XML 22 R43.htm IDEA: XBRL DOCUMENT
v3.3.0.814

Segments of Business and Geographic Areas (Details 1) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended
--- | --- | ---
Sep. 27, 2015 | Jun. 28, 2015 | Sep. 28, 2014 | Sep. 27, 2015 | Sep. 28, 2014
Segment Reporting Information [Line Items] |  |  |  |  |  |
Net gain on sale of assets/businesses |  |  |  |  | $ 1,274 | $ 2,336
Asset write-downs |  |  |  |  | $ 367 | 259
Percentage Change in Operating Income Loss |  | (39.50%) |  |  | (13.60%) |
Earnings before provision for taxes on income |  | $ 4,122 |  | $ 6,810 | $ 15,438 | 17,860
Consumer |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |
Net gain on sale of assets/businesses |  | 229 |  |  | 229 | $ 388
Pharmaceutical |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |
Net gain on sale of assets/businesses |  |  | $ 981 |  | 981 |
Other Expenses |  |  |  | $ 220 |  | $ 220
Litigation Expense |  |  |  |  | 136 |
Medical Devices |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |
Net gain on sale of assets/businesses |  |  |  | $ 1,948 |  | $ 1,948
Litigation Expense |  | 409 |  | 225 |  | 501
Asset write-downs |  | 300 |  |  | 300 |
Integration costs related to a business acquisition |  |  |  | 167 | 113 | 429
Product Liability Accrual, Period Expense |  |  |  | $ 126 | 148 | $ 126
Corporate and Other |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |
Litigation Expense |  |  |  |  |  |
Operating Segments [Member] |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |
Total Segment Operating Income |  | $ 4,378 |  | $ 7,053 | $ 16,228 | $ 18,578
Percentage Change in Operating Income Loss |  | (37.90%) |  |  | (12.60%) |
Operating Segments [Member] | Consumer |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |
Total Segment Operating Income | [1] | $ 811 |  | 407 | $ 1,772 | 1,588
Percentage Change in Operating Income Loss |  | 99.30% |  |  | 11.60% |
Operating Segments [Member] | Pharmaceutical |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |
Total Segment Operating Income | [2] | $ 2,732 |  | 3,247 | $ 9,816 | 9,921
Percentage Change in Operating Income Loss |  | (15.90%) |  |  | (1.10%) |
Operating Segments [Member] | Medical Devices |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |
Total Segment Operating Income | [3] | $ 835 |  | 3,399 | $ 4,640 | 7,069
Percentage Change in Operating Income Loss |  | (75.40%) |  |  | (34.40%) |
Corporate, Non-Segment [Member] |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |
Total Segment Operating Income | [4] | $ 256 |  | $ 243 | $ 790 | $ 718
[1] | Includes a gain of $229 million from the divestiture of the SPLENDA® brand recorded in the fiscal third quarter and fiscal nine months of 2015. Includes a gain of $388 million from the divestiture of the K-Y® brand recorded in the fiscal nine months of 2014.
[2] | Includes litigation expense of $136 million in the fiscal nine months of 2015. Includes a gain of $981 million recorded in the fiscal nine months of 2015 from the divestiture of the U.S. license rights to NUCYNTA® (tapentadol), NUCYNTA® ER (tapentadol extended-release tablets), and NUCYNTA® (tapentadol) oral solution. Includes an additional year of the Branded Prescription Drug Fee of $220 million recorded in the fiscal third quarter and fiscal nine months of 2014.
[3] | Includes litigation expense of $409 million related to product liability and a $0.3 billion intangible asset write-down related to Acclarent recorded in the fiscal third quarter of 2015. Includes a net gain of $1,948 million from the divestiture of the Ortho-Clinical Diagnostics business, litigation expense of $225 million, Synthes integration costs of $167 million and $126 million for costs associated with the DePuy ASRTM Hip program recorded in the fiscal third quarter of 2014. Includes $148 million for costs associated with the DePuy ASRTM Hip program, Synthes integration costs of $113 million and a $0.3 billion intangible asset write-down related to Acclarent recorded in the fiscal nine months of 2015. Includes a net gain of $1,948 million from the divestiture of the Ortho-Clinical Diagnostics business, litigation expense of $501 million, Synthes integration costs of $429 million and $126 million for costs associated with the DePuy ASRTM Hip program recorded in the fiscal nine months of 2014.
[4] | Amounts not allocated to segments include interest income/expense and general corporate income/expense.

X
- Definition Integration/transaction costs and currency related to a Business Acquisition. + References No definition available. + Details
Name: | jnj_IntegrationTransactionCostsAndCurrencyRelatedToBusinessAcquisition
Namespace Prefix: | jnj_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Litigation expense. + References No definition available. + Details
Name: | jnj_LitigationExpense
Namespace Prefix: | jnj_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Percentage change in operating income loss. + References No definition available. + Details
Name: | jnj_PercentageChangeInOperatingIncomeLoss
Namespace Prefix: | jnj_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=51824106&loc=d3e2420-110228 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585 + Details
Name: | us-gaap_AssetImpairmentCharges
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value. + References No definition available. + Details
Name: | us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Sum of operating profit and nonoperating income or expense before Income or Loss from equity method investments, income taxes, extraordinary items, and noncontrolling interest. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(h)(1)(i)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 + Details
Name: | us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The net result for the period of deducting operating expenses from operating revenues. + References No definition available. + Details
Name: | us-gaap_OperatingIncomeLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition This element represents a sum total of expenses not separately reflected on the income statement for the period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.7) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4,6) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details
Name: | us-gaap_OtherExpenses
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of loss reported during the period pertaining to product liability. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349 + Details
Name: | us-gaap_ProductLiabilityAccrualPeriodExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateAndOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |